Ex-FDA chief faces fine for conflict of interest

5 February 2007

Former US Food and Drug Administration Commissioner Lester Crawford, who resigned in September 2005 shortly after being confirmed by the US Senate (Marketletters passim), is expected to avoid jail but pay a fine on charges of false reporting and conflicts of interest.

In October last year, Dr Crawford pleaded guilty to two charges that could each have carried a year's imprisonment. Prosecutors claimed that Dr Crawford, or his wife, traded stock in FDA-regulated firms while he was a Deputy Commissioner and later Commissioner at the federal government agency. He failed to disclose the share holdings and allegedly made false statements about them to Department of Justice investigators.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight